Risk factors for acquisition of imipenem-resistant Acinetobacter baumannii: a case-control study

Clicks: 358
ID: 272950
2004
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Steady

Ranked #37 of 105 articles by views in Antimicrobial agents and chemotherapy

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Risk factors for the nosocomial occurrence of imipenem-resistant Acinetobacter baumannii (IRAB) were determined. A case-control study design was used for a comparison of two groups of A. baumannii-positive patients with control patients. Nosocomial IRAB was isolated from the first group of A. bauman …
Reference Key
so2004antimicrobialrisk Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Lee SO;Kim NJ;Choi SH;Hyong Kim T;Chung JW;Woo JH;Ryu J;Kim YS;;
Journal Antimicrobial agents and chemotherapy
Year 2004
DOI
DOI not found
URL
http://www.ncbi.nlm.nih.gov/pubmed/14693543
Keywords
National Center for Biotechnology Information NCBI NLM MEDLINE humans pubmed abstract nih national institutes of health national library of medicine logistic models research support non-u.s. gov't adult female male aged middle aged risk factors Bacterial drug resistance case-control studies cross infection / microbiology intensive care units cross infection / epidemiology* cross infection / drug therapy acinetobacter infections / microbiology imipenem / therapeutic use cephalosporins / therapeutic use imipenem / pharmacology* thienamycins / pharmacology* pmid:14693543 pmc310160 doi:10.1128/aac.48.1.224-228.2004 sang-oh lee nam joong kim yang soo kim acinetobacter infections / drug therapy acinetobacter infections / epidemiology* acinetobacter baumannii* thienamycins / therapeutic use

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.